[Click eStock] "Vuno, the First Year of Overseas Expansion"

On the 19th, Hana Securities stated regarding Vuno, which is preparing for overseas expansion, "Currently, the North American market is being targeted as the main focus, and entry into the Japanese market is also possible in the future," and it is expected that North American performance will be fully reflected starting next year.

Vuno's flagship product, DeepCARS, is an artificial intelligence medical device that predicts the risk of cardiac arrest in hospitalized patients and is currently undergoing FDA approval in the United States. In the U.S., insurance reimbursement rates are generally more than three times higher than those in Korea. Currently, the domestic average selling price (ASP) of DeepCARS is around 7,000 KRW. If the application for the U.S. innovative insurance reimbursement (NTAP) is submitted in October, it is expected to be reflected in performance starting next year.

The DeepBrain solution, which supports the diagnosis of major degenerative brain diseases such as Alzheimer's disease and vascular dementia, was officially launched in the U.S. market in July last year. Discussions with potential clients are still ongoing.

Analyst Kim Seong-ho analyzed, "The main growth driver for Vuno in the North American market will be the establishment of the DeepCARS solution."

According to Vuno's preliminary consolidated financial statements for last year, sales reached 25.9 billion KRW, a sharp increase of 94.8% compared to the previous year. However, due to DeepCARS commission fees and overseas certification costs, there was an operating loss of 12.4 billion KRW.

Hana Securities expects Vuno's sales this year to grow by 52.3% year-on-year to 39.4 billion KRW.